BFRI
BFRI
NASDAQ · Pharmaceuticals

Biofrontera Inc

$1.00
+0.00 (+0.02%)
Financial Highlights (FY 2026)
Revenue
52.49M
Net Income
-13,261,703
Gross Margin
73.7%
Profit Margin
-25.3%
Rev Growth
+13.3%
D/E Ratio
0.44
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 73.7% 73.7% 59.5% 59.5%
Operating Margin -27.2% -24.5% 39.9% 36.7%
Profit Margin -25.3% -24.0% 28.1% 33.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 52.49M 46.33M 1.67M 1.59M
Gross Profit 38.69M 34.15M 993.6K 946.5K
Operating Income -14,283,537 -11,345,144 666.0K 584.8K
Net Income -13,261,703 -10,533,521 470.0K 528.6K
Gross Margin 73.7% 73.7% 59.5% 59.5%
Operating Margin -27.2% -24.5% 39.9% 36.7%
Profit Margin -25.3% -24.0% 28.1% 33.2%
Rev Growth +13.3% +13.3% +24.3% +24.6%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 1.92M 1.92M 868.4K 1.11M
Total Equity 4.39M 4.39M 5.54M 6.06M
D/E Ratio 0.44 0.44 0.16 0.18
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -14,110,564 -11,830,408 856.8K 789.7K
Free Cash Flow 585.2K 384.5K